- Home
- TC vs MIRA Comparison
TC vs MIRA Comparison
Compare TC & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TC | MIRA |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 33.7M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TC | MIRA |
|---|---|---|
| Price | $12.50 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 198.1K |
| Earning Date | 12-16-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,115,721.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.20 | $0.73 |
| 52 Week High | $39.00 | $2.45 |
Technical Indicators
Market Signals| Indicator | TC | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 25.45 | 57.39 |
| Support Level | $14.43 | $1.44 |
| Resistance Level | $15.88 | $1.53 |
| Average True Range (ATR) | 1.50 | 0.07 |
| MACD | -0.54 | 0.01 |
| Stochastic Oscillator | 23.66 | 90.63 |
Price Performance
Historical ComparisonAbout TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.